Cagrilintide CAS 1415456-99-3 with COA
20 USD
Research tool for obesity mechanisms and combination therapy development.
Pharmaceutical candidate for metabolic disorders, including type 2 diabetes and obesity-related comorbidities.
Research tool for obesity mechanisms and combination therapy development.
Pharmaceutical candidate for metabolic disorders, including type 2 diabetes and obesity-related comorbidities.
Comentarii Facebook